Tirzepatide (Mounjaro) , a dual GIP/GLP-1 receptor agonist, has also received MHRA approval and NICE recommendation for weight management in eligible adults, with similar requirements for specialist service delivery and specific BMI and comorbidity criteria
The market movements were caused by the positive results on the phase 2 drug candidate LY3298176
Impurities or incorrect peptide sequences can cause unpredictable off-target effects, including metabolic disruption
This new option can provide a sustainable approach that helps your body work with you, not against you.
A total of 898 patients were evaluated, of which 13.2% had post-traumatic stress disorder, 21.0% suffered from depression, and 16.4% presented MDD (Chen et al
[Abstract]2022 Jun 15;208(12):2652-2662